INTRODUCTION
Tyrosine kinase inhibitors targeting BCR/ABL have revolutionized the treatment of CML, changing its prognosis from an overall survival of 5 years to near normal life-expectancy. 3,6 However, TKIs are associated with potentially serious complications, such as pleural effusion, pneumonitis, and vascular and metabolic disorders.1,2 Bosutinib is a BCR/ABL inhibitor used in frontline treatment of CML or in treatment of chronic, accelerated, or blast phase CML resistant or intolerant to prior TKIs. 3-6 The most common side effects are gastrointestinal, followed by thrombocytopenia and abnormal liver function tests.5However, there have been cases reporting pulmonary injury related to bosutinib. 7 Here, we discuss a case of bosutinib-induced interstitial lung disease and pleural effusion.